Adding CT contrast policy to EMR enhances safety
Partners Healthcare System in Boston has integrated CT contrast media guidelines into its electronic medical record to encourage physicians to comply with the safety standards and to cut costs for the hospitals in its network.
Partners Healthcare System in Boston has integrated CT contrast media guidelines into its electronic medical record to encourage physicians to comply with the safety standards and to cut costs for the hospitals in its network.
In 2003 Partners' radiology administrative director Kathryn McCullough and members of the Partners CT Contrast Media Team started to assess contrast media administration guidelines and screening procedures for patients at risk for contrast reactions at the system's six hospitals.
After discovering wide variations in policies and procedures, they developed a standard code for contrast media administration plus a patient questionnaire and adverse reaction form, all available through the EMR. The initiative has allowed them to identify patients with a history of prior contrast reactions. The group published its results in the Journal of the American College of Radiology (JACR 2009;6:562-566).
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
